Abstrakt

Przypisy

• 1. Andrew D.P., Chang M.S., McNinch J., Wathen S.T., Rihanek M.,Tseng J., Spellberg J.P., Elias C.G.3rd: STCP-1 (MDC) CC chemokineacts specifically on chronically activated Th2 lymphocytes and isproduced by monocytes on stimulation with Th2 cytokines IL-4 andIL-13. J. Immunol., 1998; 161: 5027-5038
  Google Scholar
• 2. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A.: Trendsof cervical cancer mortality in the member states of the EuropeanUnion. Eur. J. Cancer, 2009; 45: 2640-2648
  Google Scholar
• 3. Brinton L.A.: Epidemiology of cervical cancer – overview. IARCSci. Publ., 1992; 119: 3-23
  Google Scholar
• 4. David M.P., Van Herck K., Hardt K., Tibaldi F., Dubin G., DescampsD., Van Damme P.: Long-term persistence of anti-HPV-16 and -18 antibodiesinduced by vaccination with the AS04-adjuvanted cervicalcancer vaccine: modeling of sustained antibody responses. Gynecol.Oncol., 2009; 115 (Suppl. 3): S1-S6
  Google Scholar
• 5. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De BorbaP., Zahaf T., Sanchez N., Schuind A.: Sustained efficacy and immunogenicityof the HPV-16/18 ASO4-adjuvanted vaccine up to 7,3 yearsin young adult women. Vaccine, 2010; 28: 6247-6255
  Google Scholar
• 6. Doorbar J.: Molecular biology of human papillomavirus infectionand cervical cancer. Clin. Sci., 2006; 110: 525-541
  Google Scholar
• 7. Doorbar J.: The papillomavirus life cycle. J. Clin. Virol., 2005; 32(Suppl. 1): S7-S15
  Google Scholar
• 8. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P.,Tan T., Halsey N., Jenkins D.: Clinician’s guide to human papillomavirusimmunology: knowns and unknowns. Lancet Infect. Dis., 2009; 9: 347-356
  Google Scholar
• 9. Franco E.L., Duarte-Franco E., Ferenczy A.: Cervical cancer: epidemiology,prevention and the role of human papillomavirus infection.CMAJ, 2001; 164: 1017-1025
  Google Scholar
• 10. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., GiulianoA.R., Barr E., Ault K.A.: Modeling the long- term antibody responseof a human papillomavirus (HPV) virus-like particle (VLP) type 16prophylactic vaccine. Vaccine, 2007; 25: 4324-4333
  Google Scholar
• 11. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L.,Kirnbauer R., Roden R.B., Lowy D.R., Kast W.M., Schiller J.T.: Chimericpapillomavirus virus-like particles elicit antitumor immunityagainst the E7 oncoprotein in an HPV16 tumor model. Proc. Natl.Acad. Sci. USA, 1998; 95: 1800-1805
  Google Scholar
• 12. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D.,Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-MartinsC.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., et al.: Efficacyof a bivalent L1 virus-like particle vaccine in prevention of infectionwith human papillomavirus types 16 and 18 in young women: a randomizedcontrolled trial. Lancet, 2004; 364: 1757-1765
  Google Scholar
• 13. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., ReynoldsM.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., DillnerJ., Schiller J.T., Lowy D.R.: Safety and immunogenicity trial in adultvolunteers of a human papillomavirus 16 L1 virus-like particle vaccine.J. Natl. Cancer Inst., 2001; 93: 284-492
  Google Scholar
• 14. Hildesheim A., Schiffman M., Bromley C., Wacholder S., HerreroR., Rodriguez A., Bratti M.C., Sherman M.E., Scarpidis U., LinQ.Q., Terai M., Bromley R.L., Buetow K., Apple R.J., Burk R.D.: Humanpapillomavirus type 16 variants and risk of cervical cancer. J. Natl.Cancer Inst., 2001; 93: 315-318
  Google Scholar
• 15. Hogenesch H.: Mechanisms of stimulation of the immune responseby aluminum adjuvants. Vaccine, 2002; 20 (Suppl. 3): S34-S39
  Google Scholar
• 16. Holm T.L., Nielsen J., Claesson M.H.: CD4+CD25+ regulatory T cells:I. Phenotype and physiology. APMIS, 2004; 112: 629-641
  Google Scholar
• 17. Kim K.H., Dishongh R., Santin A.D., Cannon M.J., Bellone S.,Nakagawa M.: Recognition of a cervical cancer derived tumor cellline by a human papillomavirus type 16 E6 52-61-specific CD8 T cellclone. Cancer Immun., 2006; 30: 6: 9
  Google Scholar
• 18. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T.: PapillomavirusL1 major capsid protein self-assembles into virus-likeparticles that are highly immunogenic. Proc. Natl. Acad. Sci. USA,1992; 89: 12180-12184
  Google Scholar
• 19. Liu X.S., Xu Y., Hardy L., Khammanivong V., Zhao W., FernandoG.J., Leggatt G.R., Frazer I.H.: IL-10 mediates suppression of the CD8T cell IFN-g response to a novel viral epitope in a primed host. J.Immunol., 2003; 171: 4765-4772
  Google Scholar
• 20. Moscicki A.B., Schiffman M., Kjaer S., Villa L.L.: Updating thenatural history of HPV and anogenital cancer. Vaccine, 2006; 24(Suppl. 3): S42-S51
  Google Scholar
• 21. Muñoz N., Manalastas R. Jr., Pitisuttithum P., Tresukosol D.,Monsonego J., Ault K., Clavel C., Luna J., Myers E., Hood S., BautistaO., Bryan J., Taddeo F.J., Esser M.T., Vuocolo S., et al.: Safety, immunogenicity,and efficacy of quadrivalent human papillomavirus (types6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised,double-blind trial. Lancet, 2009; 373: 1949-1957
  Google Scholar
• 22. Oerke S., Höhn H., Zehbe I., Pilch H., Schicketanz K.H., HitzlerW.E., Neukirch C., Freitag K., Maeurer M.J.: Naturally processed andHLA-B8-presented HPV16 E7 epitope recognized by T cells from patientswith cervical cancer. Int. J. Cancer., 2005; 114: 766-778
  Google Scholar
• 23. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., WheelerC.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de CarvalhoN.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., etal.; HPV PATRICIA study group: Efficacy of a prophylactic adjuvantedbivalent L1 virus-like-particle vaccine against infection with humanpapillomavirus types 16 and 18 in young women: an interim analysisof a phase III double-blind, randomized controlled trial. Lancet,2007; 369: 2161-2170
  Google Scholar
• 24. Parkin D.M.: The global health burden of infection-associatedcancers in the year 2002. Int. J. Cancer, 2006; 118: 3030-3044
  Google Scholar
• 25. Pinto L.A., Castle P.E., Roden R.B., Harro C.D., Lowy D.R., SchillerJ.T., Wallace D., Williams M., Kopp W., Frazer I.H., Berzofsky J.A.,Hildesheim A.: HPV-16 L1 VLP vaccine elicits a broad-spectrum ofcytokine responses in whole blood. Vaccine, 2005; 23: 3555-3364
  Google Scholar
• 26. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., SchillerJ.T., Wallace D., Kopp W., Adelsberger J.W., Baseler M.W., BerzofskyJ.A., Hildesheim A.: Cellular immune responses to human papillomavirus(HPV)-16 L1 in healthy volunteers immunized with recombinantHPV-16 L1 virus-like particles. J. Infect. Dis. 2003; 188: 327-338
  Google Scholar
• 27. Stanley M.: HPV – immune response to infection and vaccination.Infect. Agent. Cancer, 2010; 5: 19
  Google Scholar
• 28. van Scott M.R., Justice J.P., Bradfield J.F., Enright E., SigounasA., Sur S.: IL-10 reduces Th2 cytokine production and eosinophiliabut augments airway reactivity in allergic mice. Am. J. Physiol. LungCell. Mol. Physiol., 2000; 278: 667-674
  Google Scholar
• 29. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., AndradeR.P., Brown D.R., Ferenczy A., Harper D.M., Koutsky L.A., Kurman R.J.,Lehtinen M., Malm C., Olsson S.E., Ronnett B.M., et al.: Immunologicresponses following administration of a vaccine targeting humanpapillomavirus types 6, 11, 16 and 18. Vaccine, 2006; 24: 5571-5583
  Google Scholar
• 30. VVilla L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J.,Iversen O.E., Olsson S.E., Hoye J., Steinwall M., Riis-Johannessen G.,Andersson-Ellstrom A., Elfgren K., von Krogh G., Lehtinen M., MalmC., et al.: High sustained efficacy of a prophylactic quadrivalent humanpapillomavirus types 6/11/16/18 L1 virus-like particle vaccinethrough 5 years of follow-up. Br. J. Cancer, 2006; 95: 1459-1466
  Google Scholar
• 31. Woo M.K., An J.M., Kim J.D., Park S.N., Kim H.J.: Expression andpurification of human papillomavirus 18 L1 virus-like particle fromSaccharomyces cerevisiae. Arch. Pharm. Res., 2008; 31: 205-209
  Google Scholar
• 32. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H.: Expression of vacciniarecombinant HPV 16 L1 and L2 ORF proteins in epithelial cells issufficient for assembly of HPV virion-like particles. Virology, 1991;185: 251-257
  Google Scholar

Pełna treść artykułu